Blicant:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Roland Valdes, Jr. et al.

Examiner: Edward J. Webn

Serial No.:

09/503,559

Group Art Unit: 1617

February 11, 2000 DIHYDROOUABAIN-LIKE FACTOR AND DIAGNOSTIC & THERAPEUTIC

Docket: 1160.003US1

COMPOSITIONS AND METHODS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(2), Applicants have included the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p). Please charge any additional fees or credit any overpayment to Account No. 19-0743.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

ROLAND VALDES, JR. ET AL.

By their Representatives,

04/10/2003 CNGUYEN 00000025 09503559

02 FC:1806

180,00 OP

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 373-6961

Date 31 Than

Ann S. Viksnins Reg. No. 37,748

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 31st day of March, 2003.

Name

Signature